Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: A randomized comparative trial with eprex

Clinical Laboratory

Volumn 58, Issue 11-12, 2012, Pages 1179-1185

  Beiraghdar, Fatemeh ^a   Panahi, Yunes ^a   Einollahi, Behzad ^a   Torkaman, Mohammad ^a   Mohammadi, Romina ^b   Marzony, Eisa Tahmasbpour ^a   Sahebkar, Amirhossein ^c,d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anemia; Bioequivalency; Biogeneric; Erythropoietin; Kidney; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CREATINE KINASE; CREATININE; EPOLYREC; FERRITIN; GENERIC DRUG; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; POTASSIUM; RECOMBINANT ERYTHROPOIETIN; SODIUM; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD CELL COUNT; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; ELECTROLYTE BALANCE; ELECTROLYTE BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; HEADACHE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE PRURITUS; INJECTION SITE RASH; IRON BINDING CAPACITY; IRON BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MYASTHENIA; MYOCARDIAL DISEASE; NAUSEA; POSTOPERATIVE COMPLICATION; POSTTRANSPLANTATION ANEMIA; RANDOMIZED CONTROLLED TRIAL; RASH; RETICULOCYTE COUNT; SEIZURE; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VOMITING;

ANEMIA; CREATINE KINASE; DOUBLE-BLIND METHOD; DRUGS, GENERIC; ERYTHROPOIETIN; HEMATOCRIT; HEMOGLOBINS; HUMANS; IRON; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER FUNCTION TESTS; RECOMBINANT PROTEINS;

EID: 84871534595     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.111223     Document Type: Article

References (26)

1. Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, Andreoni KA. Late post-transplant anemia in adult renal transplant recipients. An unrecognized problem? Am J Transplant 2002;2:429-35. (Pubitemid 36306883)
2. Yorgin PD, Belson A, Sanchez J, et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002;40:1306-18. (Pubitemid 35403145)
3. Anonymous. European Best Practice Guidelines II Working Group: Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19 (suppl 2):ii1-47.
4. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J Am Soc Nephrol 2005;16:3403-10. (Pubitemid 46179344)
5. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;38:955-62. (Pubitemid 32912694)
6. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995;60:451-7.
7. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: Risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002;13:1084-90. (Pubitemid 34274107)
8. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003;14:462-8. (Pubitemid 36150871)
9. Ponticelli C, Villa M. Role of anaemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant 2002; 17 (Suppl 1):41-6. (Pubitemid 34157118)
10. Foley R, Parfrey P, Samak M. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9 (12 Suppl):S16-23.
11. Anonymous. NKF-K/DOQI clinical practice guidelines for anaemia of chronic kidney disease, update 2000. Am J Kidney Dis 2001;37 (Suppl 1):S182-238.
12. Erslev AJ, Besarb A. The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 1995;126:283-6.
13. Cavdar C, Camsari T, Semin I, Gönenc S, Acikgöz O. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997;31:371-5. (Pubitemid 27364463)
14. McDougall IC, LewisNP, SaundersMJ, et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990;335:489-93. (Pubitemid 20073052)
15. Valderrabano F. Erythropoietin in chronic renal failure. Kidney Int 1996;50:1373-91. (Pubitemid 26342832)
16. Baltar J, Moran N, Ortega F, et al. Erythropoietin safety and efficacy in chronic allograft nephropathy. Transplant Proc 2007;39:2245-7. (Pubitemid 47418132)
17. Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant 1996;11:1815-21. (Pubitemid 26297569)
18. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005;79:367-8. (Pubitemid 40299548)
19. Patel TV, Robinson K, Singh AK. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues 2007;21:57,59,63-4.
20. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005;16 (Suppl 1):S67-9. (Pubitemid 41725087)
21. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-32. (Pubitemid 38072623)
22. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-10. (Pubitemid 15130833)
23. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986;2:1175-8.
24. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8. (Pubitemid 17052741)
25. Grzeszczak W, Sulowicz W, Rutkowski B, et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin b in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005;20:936-44. (Pubitemid 40704030)
26. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin b: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000;15:2014-9.